The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Improved glycaemic control with dipeptidyl peptidase‐4 inhibition in patients with type 2 diabetes: vildagliptin (LAF237) dose response
Abstract
Objective: A novel treatment option for diabetic patients is the enhancement of incretin hormone activity by inhibition of the enzyme dipeptidyl peptidase‐4 (DPP‐4). This study was designed to establish a dose of the DPP‐4‐inhibitor vildagliptin (LAF237) that was effective in reducing HbA1c levels and was safe and well tolerated in patients with type 2 diabetes. Patients and Methods: The study of 279 patients with type 2 diabetes consisted of a 4‐week run‐in phase where patients received placebo and a 12‐week active treatment phase where they received one of the following dosages of vildagliptin: 25 mg twice daily, 25, 50 or 100 mg once daily (qd), or placebo. Results: There was a statistically significant reduction in HbA1c levels in the vildagliptin 50 mg qd (p = 0.003) and 100 mg qd groups (p = 0.004) compared with the placebo group. The mean 4‐h postprandial glucose level was significantly reduced from placebo in the vildagliptin 50 mg qd group (p = 0.012) and mean 4‐h postprandial insulin was significantly increased from baseline vs. placebo in the vildagliptin 100 mg qd group (p = 0.022). The assessment of β‐cell function (HOMA‐B) was significantly increased in the vildagliptin 100 mg qd treatment group (p = 0.007). The incidence of adverse events was similar in all treatment groups including placebo. Conclusions: Vildagliptin, at 50 and 100 mg qd, was effective in reducing HbA1c levels compared with placebo in patients with type 2 diabetes. Vildagliptin at dosages up to 100 mg qd appeared safe and well tolerated.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F., & Turner, R. C. (1985) · Diabetologia · doi:10.1007/bf00280883 · Cited by 31,502
Zander, M., Madsbad, S., Madsen, J. L., & Holst, J. J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07952-7 · Cited by 1,297
Cited by
Dipeptidyl peptidase‐4 inhibitors in the treatment of type 2 diabetes: a comparative review
Deacon, C. F. (2011) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01306.x · Cited by 525
Bosi, E., Camisasca, R. P., Collober, C., Rochotte, E., & Garber, A. J. (2007) · Diabetes Care · doi:10.2337/dc06-1732 · Cited by 447
Kim, Y. G., Hahn, S., Oh, T. J., Kwak, S. H., Park, K. S., & Cho, Y. M. (2013) · Diabetologia · doi:10.1007/s00125-012-2827-3 · Cited by 396
BARNETT, A. (2006) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2006.01178.x · Cited by 391
Dunning, B. E., & Gerich, J. E. (2007) · Endocrine Reviews · doi:10.1210/er.2006-0026 · Cited by 369
Metadata
- Authors
- Ristic, S., Byiers, S., Foley, J., & Holmes, D.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2005-09
- Volume
- 7
- Issue
- 6
- Pages
- 692-698
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W2049323977
- Cited by
- 248
- References
- 2
- FWCI
- 19.89
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Improved glycaemic control with dipeptidyl peptidase‐4 inhibition in patients with type 2 diabetes: vildagliptin (LAF237) dose response. https://app.cochat.ai/papers/10.1111/j.1463-1326.2005.00539.x
- The paper
- Ristic, S., Byiers, S., Foley, J., & Holmes, D. (2005). Improved glycaemic control with dipeptidyl peptidase‐4 inhibition in patients with type 2 diabetes: vildagliptin (LAF237) dose response. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/j.1463-1326.2005.00539.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.